Vibegron-[13C,d4]
Vibegron is a selective Beta 3 Adrenergic Receptor Agonist and was developed by Kyorin Pharmaceutical for the treatment of OAB (Overactive Bladder). Now, Vibegron is in Phase 3 human clinical trials for the treatment of OAB. In Jan 2015, Vibegron was discontinued Phase-I for hypertension (Combination therapy) in USA. In Mar 2016, Vibegron licensed to Kissei Pharmaceutical in Japan.
| Supplier | BOC Sciences |
|---|---|
| Product # | BLP-007597 |
| Pricing | Inquire |
| Molecular Weight | 449.55 |
| Molecular Formula | C25[13C]H24D4N4O3 |
| Canonical SMILES | C1CC(NC1CC2=CC=C(C=C2)NC(=O)C3CCC4=NC=CC(=O)N34)C(C5=CC=CC=C5)O |